Jean Bourhis reports on key results from ESMO Congress 2019 on LBA65: Double-blind Randomized Phase 2 Results Comparing Concurrent High-dose Cisplatin Chemorradiation (CRT) plus Debio 1143 or Placebo In High-risk Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN): A GORTEC Study
Produced by the European Society for Medical Oncology https://oncologypro.esmo.org